Global Gastrointestinal Stromal Tumor (GIST) Drug Market Growth 2025-2031
The global Gastrointestinal Stromal Tumor (GIST) Drug market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LP Information, Inc. (LPI) ' newest research report, the “Gastrointestinal Stromal Tumor (GIST) Drug Industry Forecast” looks at past sales and reviews total world Gastrointestinal Stromal Tumor (GIST) Drug sales in 2024, providing a comprehensive analysis by region and market sector of projected Gastrointestinal Stromal Tumor (GIST) Drug sales for 2025 through 2031. With Gastrointestinal Stromal Tumor (GIST) Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Gastrointestinal Stromal Tumor (GIST) Drug industry.
This Insight Report provides a comprehensive analysis of the global Gastrointestinal Stromal Tumor (GIST) Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Gastrointestinal Stromal Tumor (GIST) Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Gastrointestinal Stromal Tumor (GIST) Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Gastrointestinal Stromal Tumor (GIST) Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Gastrointestinal Stromal Tumor (GIST) Drug.
This report presents a comprehensive overview, market shares, and growth opportunities of Gastrointestinal Stromal Tumor (GIST) Drug market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Gastrointestinal Stromal Tumor (GIST) Drug market?
What factors are driving Gastrointestinal Stromal Tumor (GIST) Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Gastrointestinal Stromal Tumor (GIST) Drug market opportunities vary by end market size?
How does Gastrointestinal Stromal Tumor (GIST) Drug break out by Type, by Application?
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LP Information, Inc. (LPI) ' newest research report, the “Gastrointestinal Stromal Tumor (GIST) Drug Industry Forecast” looks at past sales and reviews total world Gastrointestinal Stromal Tumor (GIST) Drug sales in 2024, providing a comprehensive analysis by region and market sector of projected Gastrointestinal Stromal Tumor (GIST) Drug sales for 2025 through 2031. With Gastrointestinal Stromal Tumor (GIST) Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Gastrointestinal Stromal Tumor (GIST) Drug industry.
This Insight Report provides a comprehensive analysis of the global Gastrointestinal Stromal Tumor (GIST) Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Gastrointestinal Stromal Tumor (GIST) Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Gastrointestinal Stromal Tumor (GIST) Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Gastrointestinal Stromal Tumor (GIST) Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Gastrointestinal Stromal Tumor (GIST) Drug.
This report presents a comprehensive overview, market shares, and growth opportunities of Gastrointestinal Stromal Tumor (GIST) Drug market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Amcasertib
- Anagrelide hydrochloride CR
- APG-1351
- Binimetinib
- Others
- Clinic
- Hospital
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Ariad Pharmaceuticals, Inc.
- Arog Pharmaceuticals, Inc.
- Array BioPharma Inc.
- Astex Pharmaceuticals, Inc.
- Blueprint Medicines Corporation
- Boston Biomedical, Inc.
- Calithera Biosciences, Inc.
- Chipscreen Biosciences Ltd
- Deciphera Pharmaceuticals, LLC
- F. Hoffmann-La Roche Ltd.
- Horizon Pharma Plc
- Immunicum AB
- Jiangsu Hengrui Medicine Co., Ltd.
- Kolltan Pharmaceuticals, Inc.
- Natco Pharma Limited
- Nerviano Medical Sciences S.r.l.
- Novartis AG
- Omeros Corporation
What is the 10-year outlook for the global Gastrointestinal Stromal Tumor (GIST) Drug market?
What factors are driving Gastrointestinal Stromal Tumor (GIST) Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Gastrointestinal Stromal Tumor (GIST) Drug market opportunities vary by end market size?
How does Gastrointestinal Stromal Tumor (GIST) Drug break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Proto-Oncogene Drgu Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Proto-Oncogene Drgu by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Proto-Oncogene Drgu by Country/Region, 2020, 2024 & 2031
2.2 Proto-Oncogene Drgu Segment by Type
2.2.1 Axitinib (Inlyta)
2.2.2 Ponatinib (Iclusig)
2.2.3 Imatinib (Gleevec)
2.2.4 Sunitinib (Sutent)
2.2.5 Pazopanib (Votrient)
2.2.6 Dabrafenib (Tafinlar)
2.2.7 Vandetanib (Caprelsa)
2.2.8 Vemurafenib (Zelboraf)
2.2.9 Cabozantinib (Cabometyx and Cometriq)
2.3 Proto-Oncogene Drgu Sales by Type
2.3.1 Global Proto-Oncogene Drgu Sales Market Share by Type (2020-2025)
2.3.2 Global Proto-Oncogene Drgu Revenue and Market Share by Type (2020-2025)
2.3.3 Global Proto-Oncogene Drgu Sale Price by Type (2020-2025)
2.4 Proto-Oncogene Drgu Segment by Application
2.4.1 Clinic
2.4.2 Hospital
2.4.3 Others
2.5 Proto-Oncogene Drgu Sales by Application
2.5.1 Global Proto-Oncogene Drgu Sale Market Share by Application (2020-2025)
2.5.2 Global Proto-Oncogene Drgu Revenue and Market Share by Application (2020-2025)
2.5.3 Global Proto-Oncogene Drgu Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global Proto-Oncogene Drgu Breakdown Data by Company
3.1.1 Global Proto-Oncogene Drgu Annual Sales by Company (2020-2025)
3.1.2 Global Proto-Oncogene Drgu Sales Market Share by Company (2020-2025)
3.2 Global Proto-Oncogene Drgu Annual Revenue by Company (2020-2025)
3.2.1 Global Proto-Oncogene Drgu Revenue by Company (2020-2025)
3.2.2 Global Proto-Oncogene Drgu Revenue Market Share by Company (2020-2025)
3.3 Global Proto-Oncogene Drgu Sale Price by Company
3.4 Key Manufacturers Proto-Oncogene Drgu Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Proto-Oncogene Drgu Product Location Distribution
3.4.2 Players Proto-Oncogene Drgu Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR PROTO-ONCOGENE DRGU BY GEOGRAPHIC REGION
4.1 World Historic Proto-Oncogene Drgu Market Size by Geographic Region (2020-2025)
4.1.1 Global Proto-Oncogene Drgu Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Proto-Oncogene Drgu Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Proto-Oncogene Drgu Market Size by Country/Region (2020-2025)
4.2.1 Global Proto-Oncogene Drgu Annual Sales by Country/Region (2020-2025)
4.2.2 Global Proto-Oncogene Drgu Annual Revenue by Country/Region (2020-2025)
4.3 Americas Proto-Oncogene Drgu Sales Growth
4.4 APAC Proto-Oncogene Drgu Sales Growth
4.5 Europe Proto-Oncogene Drgu Sales Growth
4.6 Middle East & Africa Proto-Oncogene Drgu Sales Growth
5 AMERICAS
5.1 Americas Proto-Oncogene Drgu Sales by Country
5.1.1 Americas Proto-Oncogene Drgu Sales by Country (2020-2025)
5.1.2 Americas Proto-Oncogene Drgu Revenue by Country (2020-2025)
5.2 Americas Proto-Oncogene Drgu Sales by Type (2020-2025)
5.3 Americas Proto-Oncogene Drgu Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Proto-Oncogene Drgu Sales by Region
6.1.1 APAC Proto-Oncogene Drgu Sales by Region (2020-2025)
6.1.2 APAC Proto-Oncogene Drgu Revenue by Region (2020-2025)
6.2 APAC Proto-Oncogene Drgu Sales by Type (2020-2025)
6.3 APAC Proto-Oncogene Drgu Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Proto-Oncogene Drgu by Country
7.1.1 Europe Proto-Oncogene Drgu Sales by Country (2020-2025)
7.1.2 Europe Proto-Oncogene Drgu Revenue by Country (2020-2025)
7.2 Europe Proto-Oncogene Drgu Sales by Type (2020-2025)
7.3 Europe Proto-Oncogene Drgu Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Proto-Oncogene Drgu by Country
8.1.1 Middle East & Africa Proto-Oncogene Drgu Sales by Country (2020-2025)
8.1.2 Middle East & Africa Proto-Oncogene Drgu Revenue by Country (2020-2025)
8.2 Middle East & Africa Proto-Oncogene Drgu Sales by Type (2020-2025)
8.3 Middle East & Africa Proto-Oncogene Drgu Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Proto-Oncogene Drgu
10.3 Manufacturing Process Analysis of Proto-Oncogene Drgu
10.4 Industry Chain Structure of Proto-Oncogene Drgu
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Proto-Oncogene Drgu Distributors
11.3 Proto-Oncogene Drgu Customer
12 WORLD FORECAST REVIEW FOR PROTO-ONCOGENE DRGU BY GEOGRAPHIC REGION
12.1 Global Proto-Oncogene Drgu Market Size Forecast by Region
12.1.1 Global Proto-Oncogene Drgu Forecast by Region (2026-2031)
12.1.2 Global Proto-Oncogene Drgu Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Proto-Oncogene Drgu Forecast by Type (2026-2031)
12.7 Global Proto-Oncogene Drgu Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 ARIAD Pharmaceuticals
13.1.1 ARIAD Pharmaceuticals Company Information
13.1.2 ARIAD Pharmaceuticals Proto-Oncogene Drgu Product Portfolios and Specifications
13.1.3 ARIAD Pharmaceuticals Proto-Oncogene Drgu Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 ARIAD Pharmaceuticals Main Business Overview
13.1.5 ARIAD Pharmaceuticals Latest Developments
13.2 AstraZeneca
13.2.1 AstraZeneca Company Information
13.2.2 AstraZeneca Proto-Oncogene Drgu Product Portfolios and Specifications
13.2.3 AstraZeneca Proto-Oncogene Drgu Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 AstraZeneca Main Business Overview
13.2.5 AstraZeneca Latest Developments
13.3 Bayer Healthcare
13.3.1 Bayer Healthcare Company Information
13.3.2 Bayer Healthcare Proto-Oncogene Drgu Product Portfolios and Specifications
13.3.3 Bayer Healthcare Proto-Oncogene Drgu Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Bayer Healthcare Main Business Overview
13.3.5 Bayer Healthcare Latest Developments
13.4 Bristol-Myers Squibb
13.4.1 Bristol-Myers Squibb Company Information
13.4.2 Bristol-Myers Squibb Proto-Oncogene Drgu Product Portfolios and Specifications
13.4.3 Bristol-Myers Squibb Proto-Oncogene Drgu Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Bristol-Myers Squibb Main Business Overview
13.4.5 Bristol-Myers Squibb Latest Developments
13.5 ChemGenex Pharmaceuticals
13.5.1 ChemGenex Pharmaceuticals Company Information
13.5.2 ChemGenex Pharmaceuticals Proto-Oncogene Drgu Product Portfolios and Specifications
13.5.3 ChemGenex Pharmaceuticals Proto-Oncogene Drgu Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 ChemGenex Pharmaceuticals Main Business Overview
13.5.5 ChemGenex Pharmaceuticals Latest Developments
13.6 Dexa Medica
13.6.1 Dexa Medica Company Information
13.6.2 Dexa Medica Proto-Oncogene Drgu Product Portfolios and Specifications
13.6.3 Dexa Medica Proto-Oncogene Drgu Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Dexa Medica Main Business Overview
13.6.5 Dexa Medica Latest Developments
13.7 Eisai Pharmaceuticals
13.7.1 Eisai Pharmaceuticals Company Information
13.7.2 Eisai Pharmaceuticals Proto-Oncogene Drgu Product Portfolios and Specifications
13.7.3 Eisai Pharmaceuticals Proto-Oncogene Drgu Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Eisai Pharmaceuticals Main Business Overview
13.7.5 Eisai Pharmaceuticals Latest Developments
13.8 Exelixis
13.8.1 Exelixis Company Information
13.8.2 Exelixis Proto-Oncogene Drgu Product Portfolios and Specifications
13.8.3 Exelixis Proto-Oncogene Drgu Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Exelixis Main Business Overview
13.8.5 Exelixis Latest Developments
13.9 GlaxoSmithKline
13.9.1 GlaxoSmithKline Company Information
13.9.2 GlaxoSmithKline Proto-Oncogene Drgu Product Portfolios and Specifications
13.9.3 GlaxoSmithKline Proto-Oncogene Drgu Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 GlaxoSmithKline Main Business Overview
13.9.5 GlaxoSmithKline Latest Developments
13.10 Novartis
13.10.1 Novartis Company Information
13.10.2 Novartis Proto-Oncogene Drgu Product Portfolios and Specifications
13.10.3 Novartis Proto-Oncogene Drgu Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Novartis Main Business Overview
13.10.5 Novartis Latest Developments
13.11 Onyx Pharmaceuticals
13.11.1 Onyx Pharmaceuticals Company Information
13.11.2 Onyx Pharmaceuticals Proto-Oncogene Drgu Product Portfolios and Specifications
13.11.3 Onyx Pharmaceuticals Proto-Oncogene Drgu Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Onyx Pharmaceuticals Main Business Overview
13.11.5 Onyx Pharmaceuticals Latest Developments
13.12 Plexxikon
13.12.1 Plexxikon Company Information
13.12.2 Plexxikon Proto-Oncogene Drgu Product Portfolios and Specifications
13.12.3 Plexxikon Proto-Oncogene Drgu Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 Plexxikon Main Business Overview
13.12.5 Plexxikon Latest Developments
13.13 Pfizer
13.13.1 Pfizer Company Information
13.13.2 Pfizer Proto-Oncogene Drgu Product Portfolios and Specifications
13.13.3 Pfizer Proto-Oncogene Drgu Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 Pfizer Main Business Overview
13.13.5 Pfizer Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Proto-Oncogene Drgu Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Proto-Oncogene Drgu by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Proto-Oncogene Drgu by Country/Region, 2020, 2024 & 2031
2.2 Proto-Oncogene Drgu Segment by Type
2.2.1 Axitinib (Inlyta)
2.2.2 Ponatinib (Iclusig)
2.2.3 Imatinib (Gleevec)
2.2.4 Sunitinib (Sutent)
2.2.5 Pazopanib (Votrient)
2.2.6 Dabrafenib (Tafinlar)
2.2.7 Vandetanib (Caprelsa)
2.2.8 Vemurafenib (Zelboraf)
2.2.9 Cabozantinib (Cabometyx and Cometriq)
2.3 Proto-Oncogene Drgu Sales by Type
2.3.1 Global Proto-Oncogene Drgu Sales Market Share by Type (2020-2025)
2.3.2 Global Proto-Oncogene Drgu Revenue and Market Share by Type (2020-2025)
2.3.3 Global Proto-Oncogene Drgu Sale Price by Type (2020-2025)
2.4 Proto-Oncogene Drgu Segment by Application
2.4.1 Clinic
2.4.2 Hospital
2.4.3 Others
2.5 Proto-Oncogene Drgu Sales by Application
2.5.1 Global Proto-Oncogene Drgu Sale Market Share by Application (2020-2025)
2.5.2 Global Proto-Oncogene Drgu Revenue and Market Share by Application (2020-2025)
2.5.3 Global Proto-Oncogene Drgu Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global Proto-Oncogene Drgu Breakdown Data by Company
3.1.1 Global Proto-Oncogene Drgu Annual Sales by Company (2020-2025)
3.1.2 Global Proto-Oncogene Drgu Sales Market Share by Company (2020-2025)
3.2 Global Proto-Oncogene Drgu Annual Revenue by Company (2020-2025)
3.2.1 Global Proto-Oncogene Drgu Revenue by Company (2020-2025)
3.2.2 Global Proto-Oncogene Drgu Revenue Market Share by Company (2020-2025)
3.3 Global Proto-Oncogene Drgu Sale Price by Company
3.4 Key Manufacturers Proto-Oncogene Drgu Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Proto-Oncogene Drgu Product Location Distribution
3.4.2 Players Proto-Oncogene Drgu Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR PROTO-ONCOGENE DRGU BY GEOGRAPHIC REGION
4.1 World Historic Proto-Oncogene Drgu Market Size by Geographic Region (2020-2025)
4.1.1 Global Proto-Oncogene Drgu Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Proto-Oncogene Drgu Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Proto-Oncogene Drgu Market Size by Country/Region (2020-2025)
4.2.1 Global Proto-Oncogene Drgu Annual Sales by Country/Region (2020-2025)
4.2.2 Global Proto-Oncogene Drgu Annual Revenue by Country/Region (2020-2025)
4.3 Americas Proto-Oncogene Drgu Sales Growth
4.4 APAC Proto-Oncogene Drgu Sales Growth
4.5 Europe Proto-Oncogene Drgu Sales Growth
4.6 Middle East & Africa Proto-Oncogene Drgu Sales Growth
5 AMERICAS
5.1 Americas Proto-Oncogene Drgu Sales by Country
5.1.1 Americas Proto-Oncogene Drgu Sales by Country (2020-2025)
5.1.2 Americas Proto-Oncogene Drgu Revenue by Country (2020-2025)
5.2 Americas Proto-Oncogene Drgu Sales by Type (2020-2025)
5.3 Americas Proto-Oncogene Drgu Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Proto-Oncogene Drgu Sales by Region
6.1.1 APAC Proto-Oncogene Drgu Sales by Region (2020-2025)
6.1.2 APAC Proto-Oncogene Drgu Revenue by Region (2020-2025)
6.2 APAC Proto-Oncogene Drgu Sales by Type (2020-2025)
6.3 APAC Proto-Oncogene Drgu Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Proto-Oncogene Drgu by Country
7.1.1 Europe Proto-Oncogene Drgu Sales by Country (2020-2025)
7.1.2 Europe Proto-Oncogene Drgu Revenue by Country (2020-2025)
7.2 Europe Proto-Oncogene Drgu Sales by Type (2020-2025)
7.3 Europe Proto-Oncogene Drgu Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Proto-Oncogene Drgu by Country
8.1.1 Middle East & Africa Proto-Oncogene Drgu Sales by Country (2020-2025)
8.1.2 Middle East & Africa Proto-Oncogene Drgu Revenue by Country (2020-2025)
8.2 Middle East & Africa Proto-Oncogene Drgu Sales by Type (2020-2025)
8.3 Middle East & Africa Proto-Oncogene Drgu Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Proto-Oncogene Drgu
10.3 Manufacturing Process Analysis of Proto-Oncogene Drgu
10.4 Industry Chain Structure of Proto-Oncogene Drgu
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Proto-Oncogene Drgu Distributors
11.3 Proto-Oncogene Drgu Customer
12 WORLD FORECAST REVIEW FOR PROTO-ONCOGENE DRGU BY GEOGRAPHIC REGION
12.1 Global Proto-Oncogene Drgu Market Size Forecast by Region
12.1.1 Global Proto-Oncogene Drgu Forecast by Region (2026-2031)
12.1.2 Global Proto-Oncogene Drgu Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Proto-Oncogene Drgu Forecast by Type (2026-2031)
12.7 Global Proto-Oncogene Drgu Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 ARIAD Pharmaceuticals
13.1.1 ARIAD Pharmaceuticals Company Information
13.1.2 ARIAD Pharmaceuticals Proto-Oncogene Drgu Product Portfolios and Specifications
13.1.3 ARIAD Pharmaceuticals Proto-Oncogene Drgu Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 ARIAD Pharmaceuticals Main Business Overview
13.1.5 ARIAD Pharmaceuticals Latest Developments
13.2 AstraZeneca
13.2.1 AstraZeneca Company Information
13.2.2 AstraZeneca Proto-Oncogene Drgu Product Portfolios and Specifications
13.2.3 AstraZeneca Proto-Oncogene Drgu Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 AstraZeneca Main Business Overview
13.2.5 AstraZeneca Latest Developments
13.3 Bayer Healthcare
13.3.1 Bayer Healthcare Company Information
13.3.2 Bayer Healthcare Proto-Oncogene Drgu Product Portfolios and Specifications
13.3.3 Bayer Healthcare Proto-Oncogene Drgu Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Bayer Healthcare Main Business Overview
13.3.5 Bayer Healthcare Latest Developments
13.4 Bristol-Myers Squibb
13.4.1 Bristol-Myers Squibb Company Information
13.4.2 Bristol-Myers Squibb Proto-Oncogene Drgu Product Portfolios and Specifications
13.4.3 Bristol-Myers Squibb Proto-Oncogene Drgu Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Bristol-Myers Squibb Main Business Overview
13.4.5 Bristol-Myers Squibb Latest Developments
13.5 ChemGenex Pharmaceuticals
13.5.1 ChemGenex Pharmaceuticals Company Information
13.5.2 ChemGenex Pharmaceuticals Proto-Oncogene Drgu Product Portfolios and Specifications
13.5.3 ChemGenex Pharmaceuticals Proto-Oncogene Drgu Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 ChemGenex Pharmaceuticals Main Business Overview
13.5.5 ChemGenex Pharmaceuticals Latest Developments
13.6 Dexa Medica
13.6.1 Dexa Medica Company Information
13.6.2 Dexa Medica Proto-Oncogene Drgu Product Portfolios and Specifications
13.6.3 Dexa Medica Proto-Oncogene Drgu Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Dexa Medica Main Business Overview
13.6.5 Dexa Medica Latest Developments
13.7 Eisai Pharmaceuticals
13.7.1 Eisai Pharmaceuticals Company Information
13.7.2 Eisai Pharmaceuticals Proto-Oncogene Drgu Product Portfolios and Specifications
13.7.3 Eisai Pharmaceuticals Proto-Oncogene Drgu Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Eisai Pharmaceuticals Main Business Overview
13.7.5 Eisai Pharmaceuticals Latest Developments
13.8 Exelixis
13.8.1 Exelixis Company Information
13.8.2 Exelixis Proto-Oncogene Drgu Product Portfolios and Specifications
13.8.3 Exelixis Proto-Oncogene Drgu Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Exelixis Main Business Overview
13.8.5 Exelixis Latest Developments
13.9 GlaxoSmithKline
13.9.1 GlaxoSmithKline Company Information
13.9.2 GlaxoSmithKline Proto-Oncogene Drgu Product Portfolios and Specifications
13.9.3 GlaxoSmithKline Proto-Oncogene Drgu Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 GlaxoSmithKline Main Business Overview
13.9.5 GlaxoSmithKline Latest Developments
13.10 Novartis
13.10.1 Novartis Company Information
13.10.2 Novartis Proto-Oncogene Drgu Product Portfolios and Specifications
13.10.3 Novartis Proto-Oncogene Drgu Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Novartis Main Business Overview
13.10.5 Novartis Latest Developments
13.11 Onyx Pharmaceuticals
13.11.1 Onyx Pharmaceuticals Company Information
13.11.2 Onyx Pharmaceuticals Proto-Oncogene Drgu Product Portfolios and Specifications
13.11.3 Onyx Pharmaceuticals Proto-Oncogene Drgu Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Onyx Pharmaceuticals Main Business Overview
13.11.5 Onyx Pharmaceuticals Latest Developments
13.12 Plexxikon
13.12.1 Plexxikon Company Information
13.12.2 Plexxikon Proto-Oncogene Drgu Product Portfolios and Specifications
13.12.3 Plexxikon Proto-Oncogene Drgu Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 Plexxikon Main Business Overview
13.12.5 Plexxikon Latest Developments
13.13 Pfizer
13.13.1 Pfizer Company Information
13.13.2 Pfizer Proto-Oncogene Drgu Product Portfolios and Specifications
13.13.3 Pfizer Proto-Oncogene Drgu Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 Pfizer Main Business Overview
13.13.5 Pfizer Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Gastrointestinal Stromal Tumor (GIST) Drug Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Gastrointestinal Stromal Tumor (GIST) Drug Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Amcasertib
Table 4. Major Players of Anagrelide hydrochloride CR
Table 5. Major Players of APG-1351
Table 6. Major Players of Binimetinib
Table 7. Major Players of Others
Table 8. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales by Type (2020-2025) & (K Pcs)
Table 9. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Type (2020-2025)
Table 10. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Type (2020-2025) & ($ million)
Table 11. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Type (2020-2025)
Table 12. Global Gastrointestinal Stromal Tumor (GIST) Drug Sale Price by Type (2020-2025) & (USD/Pcs)
Table 13. Global Gastrointestinal Stromal Tumor (GIST) Drug Sale by Application (2020-2025) & (K Pcs)
Table 14. Global Gastrointestinal Stromal Tumor (GIST) Drug Sale Market Share by Application (2020-2025)
Table 15. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Application (2020-2025) & ($ million)
Table 16. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Application (2020-2025)
Table 17. Global Gastrointestinal Stromal Tumor (GIST) Drug Sale Price by Application (2020-2025) & (USD/Pcs)
Table 18. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales by Company (2020-2025) & (K Pcs)
Table 19. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Company (2020-2025)
Table 20. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Company (2020-2025) & ($ millions)
Table 21. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Company (2020-2025)
Table 22. Global Gastrointestinal Stromal Tumor (GIST) Drug Sale Price by Company (2020-2025) & (USD/Pcs)
Table 23. Key Manufacturers Gastrointestinal Stromal Tumor (GIST) Drug Producing Area Distribution and Sales Area
Table 24. Players Gastrointestinal Stromal Tumor (GIST) Drug Products Offered
Table 25. Gastrointestinal Stromal Tumor (GIST) Drug Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 26. New Products and Potential Entrants
Table 27. Market M&A Activity & Strategy
Table 28. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales by Geographic Region (2020-2025) & (K Pcs)
Table 29. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share Geographic Region (2020-2025)
Table 30. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Geographic Region (2020-2025) & ($ millions)
Table 31. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Geographic Region (2020-2025)
Table 32. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales by Country/Region (2020-2025) & (K Pcs)
Table 33. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Country/Region (2020-2025)
Table 34. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Country/Region (2020-2025) & ($ millions)
Table 35. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Country/Region (2020-2025)
Table 36. Americas Gastrointestinal Stromal Tumor (GIST) Drug Sales by Country (2020-2025) & (K Pcs)
Table 37. Americas Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Country (2020-2025)
Table 38. Americas Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Country (2020-2025) & ($ millions)
Table 39. Americas Gastrointestinal Stromal Tumor (GIST) Drug Sales by Type (2020-2025) & (K Pcs)
Table 40. Americas Gastrointestinal Stromal Tumor (GIST) Drug Sales by Application (2020-2025) & (K Pcs)
Table 41. APAC Gastrointestinal Stromal Tumor (GIST) Drug Sales by Region (2020-2025) & (K Pcs)
Table 42. APAC Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Region (2020-2025)
Table 43. APAC Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Region (2020-2025) & ($ millions)
Table 44. APAC Gastrointestinal Stromal Tumor (GIST) Drug Sales by Type (2020-2025) & (K Pcs)
Table 45. APAC Gastrointestinal Stromal Tumor (GIST) Drug Sales by Application (2020-2025) & (K Pcs)
Table 46. Europe Gastrointestinal Stromal Tumor (GIST) Drug Sales by Country (2020-2025) & (K Pcs)
Table 47. Europe Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Country (2020-2025) & ($ millions)
Table 48. Europe Gastrointestinal Stromal Tumor (GIST) Drug Sales by Type (2020-2025) & (K Pcs)
Table 49. Europe Gastrointestinal Stromal Tumor (GIST) Drug Sales by Application (2020-2025) & (K Pcs)
Table 50. Middle East & Africa Gastrointestinal Stromal Tumor (GIST) Drug Sales by Country (2020-2025) & (K Pcs)
Table 51. Middle East & Africa Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Country (2020-2025)
Table 52. Middle East & Africa Gastrointestinal Stromal Tumor (GIST) Drug Sales by Type (2020-2025) & (K Pcs)
Table 53. Middle East & Africa Gastrointestinal Stromal Tumor (GIST) Drug Sales by Application (2020-2025) & (K Pcs)
Table 54. Key Market Drivers & Growth Opportunities of Gastrointestinal Stromal Tumor (GIST) Drug
Table 55. Key Market Challenges & Risks of Gastrointestinal Stromal Tumor (GIST) Drug
Table 56. Key Industry Trends of Gastrointestinal Stromal Tumor (GIST) Drug
Table 57. Gastrointestinal Stromal Tumor (GIST) Drug Raw Material
Table 58. Key Suppliers of Raw Materials
Table 59. Gastrointestinal Stromal Tumor (GIST) Drug Distributors List
Table 60. Gastrointestinal Stromal Tumor (GIST) Drug Customer List
Table 61. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Forecast by Region (2026-2031) & (K Pcs)
Table 62. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Forecast by Region (2026-2031) & ($ millions)
Table 63. Americas Gastrointestinal Stromal Tumor (GIST) Drug Sales Forecast by Country (2026-2031) & (K Pcs)
Table 64. Americas Gastrointestinal Stromal Tumor (GIST) Drug Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 65. APAC Gastrointestinal Stromal Tumor (GIST) Drug Sales Forecast by Region (2026-2031) & (K Pcs)
Table 66. APAC Gastrointestinal Stromal Tumor (GIST) Drug Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 67. Europe Gastrointestinal Stromal Tumor (GIST) Drug Sales Forecast by Country (2026-2031) & (K Pcs)
Table 68. Europe Gastrointestinal Stromal Tumor (GIST) Drug Revenue Forecast by Country (2026-2031) & ($ millions)
Table 69. Middle East & Africa Gastrointestinal Stromal Tumor (GIST) Drug Sales Forecast by Country (2026-2031) & (K Pcs)
Table 70. Middle East & Africa Gastrointestinal Stromal Tumor (GIST) Drug Revenue Forecast by Country (2026-2031) & ($ millions)
Table 71. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Forecast by Type (2026-2031) & (K Pcs)
Table 72. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Forecast by Type (2026-2031) & ($ millions)
Table 73. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Forecast by Application (2026-2031) & (K Pcs)
Table 74. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Forecast by Application (2026-2031) & ($ millions)
Table 75. Ariad Pharmaceuticals, Inc. Basic Information, Gastrointestinal Stromal Tumor (GIST) Drug Manufacturing Base, Sales Area and Its Competitors
Table 76. Ariad Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolios and Specifications
Table 77. Ariad Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 78. Ariad Pharmaceuticals, Inc. Main Business
Table 79. Ariad Pharmaceuticals, Inc. Latest Developments
Table 80. Arog Pharmaceuticals, Inc. Basic Information, Gastrointestinal Stromal Tumor (GIST) Drug Manufacturing Base, Sales Area and Its Competitors
Table 81. Arog Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolios and Specifications
Table 82. Arog Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 83. Arog Pharmaceuticals, Inc. Main Business
Table 84. Arog Pharmaceuticals, Inc. Latest Developments
Table 85. Array BioPharma Inc. Basic Information, Gastrointestinal Stromal Tumor (GIST) Drug Manufacturing Base, Sales Area and Its Competitors
Table 86. Array BioPharma Inc. Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolios and Specifications
Table 87. Array BioPharma Inc. Gastrointestinal Stromal Tumor (GIST) Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 88. Array BioPharma Inc. Main Business
Table 89. Array BioPharma Inc. Latest Developments
Table 90. Astex Pharmaceuticals, Inc. Basic Information, Gastrointestinal Stromal Tumor (GIST) Drug Manufacturing Base, Sales Area and Its Competitors
Table 91. Astex Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolios and Specifications
Table 92. Astex Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 93. Astex Pharmaceuticals, Inc. Main Business
Table 94. Astex Pharmaceuticals, Inc. Latest Developments
Table 95. Blueprint Medicines Corporation Basic Information, Gastrointestinal Stromal Tumor (GIST) Drug Manufacturing Base, Sales Area and Its Competitors
Table 96. Blueprint Medicines Corporation Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolios and Specifications
Table 97. Blueprint Medicines Corporation Gastrointestinal Stromal Tumor (GIST) Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 98. Blueprint Medicines Corporation Main Business
Table 99. Blueprint Medicines Corporation Latest Developments
Table 100. Boston Biomedical, Inc. Basic Information, Gastrointestinal Stromal Tumor (GIST) Drug Manufacturing Base, Sales Area and Its Competitors
Table 101. Boston Biomedical, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolios and Specifications
Table 102. Boston Biomedical, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 103. Boston Biomedical, Inc. Main Business
Table 104. Boston Biomedical, Inc. Latest Developments
Table 105. Calithera Biosciences, Inc. Basic Information, Gastrointestinal Stromal Tumor (GIST) Drug Manufacturing Base, Sales Area and Its Competitors
Table 106. Calithera Biosciences, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolios and Specifications
Table 107. Calithera Biosciences, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 108. Calithera Biosciences, Inc. Main Business
Table 109. Calithera Biosciences, Inc. Latest Developments
Table 110. Chipscreen Biosciences Ltd Basic Information, Gastrointestinal Stromal Tumor (GIST) Drug Manufacturing Base, Sales Area and Its Competitors
Table 111. Chipscreen Biosciences Ltd Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolios and Specifications
Table 112. Chipscreen Biosciences Ltd Gastrointestinal Stromal Tumor (GIST) Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 113. Chipscreen Biosciences Ltd Main Business
Table 114. Chipscreen Biosciences Ltd Latest Developments
Table 115. Deciphera Pharmaceuticals, LLC Basic Information, Gastrointestinal Stromal Tumor (GIST) Drug Manufacturing Base, Sales Area and Its Competitors
Table 116. Deciphera Pharmaceuticals, LLC Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolios and Specifications
Table 117. Deciphera Pharmaceuticals, LLC Gastrointestinal Stromal Tumor (GIST) Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 118. Deciphera Pharmaceuticals, LLC Main Business
Table 119. Deciphera Pharmaceuticals, LLC Latest Developments
Table 120. F. Hoffmann-La Roche Ltd. Basic Information, Gastrointestinal Stromal Tumor (GIST) Drug Manufacturing Base, Sales Area and Its Competitors
Table 121. F. Hoffmann-La Roche Ltd. Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolios and Specifications
Table 122. F. Hoffmann-La Roche Ltd. Gastrointestinal Stromal Tumor (GIST) Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 123. F. Hoffmann-La Roche Ltd. Main Business
Table 124. F. Hoffmann-La Roche Ltd. Latest Developments
Table 125. Horizon Pharma Plc Basic Information, Gastrointestinal Stromal Tumor (GIST) Drug Manufacturing Base, Sales Area and Its Competitors
Table 126. Horizon Pharma Plc Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolios and Specifications
Table 127. Horizon Pharma Plc Gastrointestinal Stromal Tumor (GIST) Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 128. Horizon Pharma Plc Main Business
Table 129. Horizon Pharma Plc Latest Developments
Table 130. Immunicum AB Basic Information, Gastrointestinal Stromal Tumor (GIST) Drug Manufacturing Base, Sales Area and Its Competitors
Table 131. Immunicum AB Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolios and Specifications
Table 132. Immunicum AB Gastrointestinal Stromal Tumor (GIST) Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 133. Immunicum AB Main Business
Table 134. Immunicum AB Latest Developments
Table 135. Jiangsu Hengrui Medicine Co., Ltd. Basic Information, Gastrointestinal Stromal Tumor (GIST) Drug Manufacturing Base, Sales Area and Its Competitors
Table 136. Jiangsu Hengrui Medicine Co., Ltd. Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolios and Specifications
Table 137. Jiangsu Hengrui Medicine Co., Ltd. Gastrointestinal Stromal Tumor (GIST) Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 138. Jiangsu Hengrui Medicine Co., Ltd. Main Business
Table 139. Jiangsu Hengrui Medicine Co., Ltd. Latest Developments
Table 140. Kolltan Pharmaceuticals, Inc. Basic Information, Gastrointestinal Stromal Tumor (GIST) Drug Manufacturing Base, Sales Area and Its Competitors
Table 141. Kolltan Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolios and Specifications
Table 142. Kolltan Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 143. Kolltan Pharmaceuticals, Inc. Main Business
Table 144. Kolltan Pharmaceuticals, Inc. Latest Developments
Table 145. Natco Pharma Limited Basic Information, Gastrointestinal Stromal Tumor (GIST) Drug Manufacturing Base, Sales Area and Its Competitors
Table 146. Natco Pharma Limited Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolios and Specifications
Table 147. Natco Pharma Limited Gastrointestinal Stromal Tumor (GIST) Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 148. Natco Pharma Limited Main Business
Table 149. Natco Pharma Limited Latest Developments
Table 150. Nerviano Medical Sciences S.r.l. Basic Information, Gastrointestinal Stromal Tumor (GIST) Drug Manufacturing Base, Sales Area and Its Competitors
Table 151. Nerviano Medical Sciences S.r.l. Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolios and Specifications
Table 152. Nerviano Medical Sciences S.r.l. Gastrointestinal Stromal Tumor (GIST) Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 153. Nerviano Medical Sciences S.r.l. Main Business
Table 154. Nerviano Medical Sciences S.r.l. Latest Developments
Table 155. Novartis AG Basic Information, Gastrointestinal Stromal Tumor (GIST) Drug Manufacturing Base, Sales Area and Its Competitors
Table 156. Novartis AG Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolios and Specifications
Table 157. Novartis AG Gastrointestinal Stromal Tumor (GIST) Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 158. Novartis AG Main Business
Table 159. Novartis AG Latest Developments
Table 160. Omeros Corporation Basic Information, Gastrointestinal Stromal Tumor (GIST) Drug Manufacturing Base, Sales Area and Its Competitors
Table 161. Omeros Corporation Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolios and Specifications
Table 162. Omeros Corporation Gastrointestinal Stromal Tumor (GIST) Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 163. Omeros Corporation Main Business
Table 164. Omeros Corporation Latest Developments
Table 1. Gastrointestinal Stromal Tumor (GIST) Drug Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Gastrointestinal Stromal Tumor (GIST) Drug Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Amcasertib
Table 4. Major Players of Anagrelide hydrochloride CR
Table 5. Major Players of APG-1351
Table 6. Major Players of Binimetinib
Table 7. Major Players of Others
Table 8. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales by Type (2020-2025) & (K Pcs)
Table 9. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Type (2020-2025)
Table 10. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Type (2020-2025) & ($ million)
Table 11. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Type (2020-2025)
Table 12. Global Gastrointestinal Stromal Tumor (GIST) Drug Sale Price by Type (2020-2025) & (USD/Pcs)
Table 13. Global Gastrointestinal Stromal Tumor (GIST) Drug Sale by Application (2020-2025) & (K Pcs)
Table 14. Global Gastrointestinal Stromal Tumor (GIST) Drug Sale Market Share by Application (2020-2025)
Table 15. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Application (2020-2025) & ($ million)
Table 16. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Application (2020-2025)
Table 17. Global Gastrointestinal Stromal Tumor (GIST) Drug Sale Price by Application (2020-2025) & (USD/Pcs)
Table 18. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales by Company (2020-2025) & (K Pcs)
Table 19. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Company (2020-2025)
Table 20. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Company (2020-2025) & ($ millions)
Table 21. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Company (2020-2025)
Table 22. Global Gastrointestinal Stromal Tumor (GIST) Drug Sale Price by Company (2020-2025) & (USD/Pcs)
Table 23. Key Manufacturers Gastrointestinal Stromal Tumor (GIST) Drug Producing Area Distribution and Sales Area
Table 24. Players Gastrointestinal Stromal Tumor (GIST) Drug Products Offered
Table 25. Gastrointestinal Stromal Tumor (GIST) Drug Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 26. New Products and Potential Entrants
Table 27. Market M&A Activity & Strategy
Table 28. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales by Geographic Region (2020-2025) & (K Pcs)
Table 29. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share Geographic Region (2020-2025)
Table 30. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Geographic Region (2020-2025) & ($ millions)
Table 31. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Geographic Region (2020-2025)
Table 32. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales by Country/Region (2020-2025) & (K Pcs)
Table 33. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Country/Region (2020-2025)
Table 34. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Country/Region (2020-2025) & ($ millions)
Table 35. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Country/Region (2020-2025)
Table 36. Americas Gastrointestinal Stromal Tumor (GIST) Drug Sales by Country (2020-2025) & (K Pcs)
Table 37. Americas Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Country (2020-2025)
Table 38. Americas Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Country (2020-2025) & ($ millions)
Table 39. Americas Gastrointestinal Stromal Tumor (GIST) Drug Sales by Type (2020-2025) & (K Pcs)
Table 40. Americas Gastrointestinal Stromal Tumor (GIST) Drug Sales by Application (2020-2025) & (K Pcs)
Table 41. APAC Gastrointestinal Stromal Tumor (GIST) Drug Sales by Region (2020-2025) & (K Pcs)
Table 42. APAC Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Region (2020-2025)
Table 43. APAC Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Region (2020-2025) & ($ millions)
Table 44. APAC Gastrointestinal Stromal Tumor (GIST) Drug Sales by Type (2020-2025) & (K Pcs)
Table 45. APAC Gastrointestinal Stromal Tumor (GIST) Drug Sales by Application (2020-2025) & (K Pcs)
Table 46. Europe Gastrointestinal Stromal Tumor (GIST) Drug Sales by Country (2020-2025) & (K Pcs)
Table 47. Europe Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Country (2020-2025) & ($ millions)
Table 48. Europe Gastrointestinal Stromal Tumor (GIST) Drug Sales by Type (2020-2025) & (K Pcs)
Table 49. Europe Gastrointestinal Stromal Tumor (GIST) Drug Sales by Application (2020-2025) & (K Pcs)
Table 50. Middle East & Africa Gastrointestinal Stromal Tumor (GIST) Drug Sales by Country (2020-2025) & (K Pcs)
Table 51. Middle East & Africa Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Country (2020-2025)
Table 52. Middle East & Africa Gastrointestinal Stromal Tumor (GIST) Drug Sales by Type (2020-2025) & (K Pcs)
Table 53. Middle East & Africa Gastrointestinal Stromal Tumor (GIST) Drug Sales by Application (2020-2025) & (K Pcs)
Table 54. Key Market Drivers & Growth Opportunities of Gastrointestinal Stromal Tumor (GIST) Drug
Table 55. Key Market Challenges & Risks of Gastrointestinal Stromal Tumor (GIST) Drug
Table 56. Key Industry Trends of Gastrointestinal Stromal Tumor (GIST) Drug
Table 57. Gastrointestinal Stromal Tumor (GIST) Drug Raw Material
Table 58. Key Suppliers of Raw Materials
Table 59. Gastrointestinal Stromal Tumor (GIST) Drug Distributors List
Table 60. Gastrointestinal Stromal Tumor (GIST) Drug Customer List
Table 61. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Forecast by Region (2026-2031) & (K Pcs)
Table 62. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Forecast by Region (2026-2031) & ($ millions)
Table 63. Americas Gastrointestinal Stromal Tumor (GIST) Drug Sales Forecast by Country (2026-2031) & (K Pcs)
Table 64. Americas Gastrointestinal Stromal Tumor (GIST) Drug Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 65. APAC Gastrointestinal Stromal Tumor (GIST) Drug Sales Forecast by Region (2026-2031) & (K Pcs)
Table 66. APAC Gastrointestinal Stromal Tumor (GIST) Drug Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 67. Europe Gastrointestinal Stromal Tumor (GIST) Drug Sales Forecast by Country (2026-2031) & (K Pcs)
Table 68. Europe Gastrointestinal Stromal Tumor (GIST) Drug Revenue Forecast by Country (2026-2031) & ($ millions)
Table 69. Middle East & Africa Gastrointestinal Stromal Tumor (GIST) Drug Sales Forecast by Country (2026-2031) & (K Pcs)
Table 70. Middle East & Africa Gastrointestinal Stromal Tumor (GIST) Drug Revenue Forecast by Country (2026-2031) & ($ millions)
Table 71. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Forecast by Type (2026-2031) & (K Pcs)
Table 72. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Forecast by Type (2026-2031) & ($ millions)
Table 73. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Forecast by Application (2026-2031) & (K Pcs)
Table 74. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Forecast by Application (2026-2031) & ($ millions)
Table 75. Ariad Pharmaceuticals, Inc. Basic Information, Gastrointestinal Stromal Tumor (GIST) Drug Manufacturing Base, Sales Area and Its Competitors
Table 76. Ariad Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolios and Specifications
Table 77. Ariad Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 78. Ariad Pharmaceuticals, Inc. Main Business
Table 79. Ariad Pharmaceuticals, Inc. Latest Developments
Table 80. Arog Pharmaceuticals, Inc. Basic Information, Gastrointestinal Stromal Tumor (GIST) Drug Manufacturing Base, Sales Area and Its Competitors
Table 81. Arog Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolios and Specifications
Table 82. Arog Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 83. Arog Pharmaceuticals, Inc. Main Business
Table 84. Arog Pharmaceuticals, Inc. Latest Developments
Table 85. Array BioPharma Inc. Basic Information, Gastrointestinal Stromal Tumor (GIST) Drug Manufacturing Base, Sales Area and Its Competitors
Table 86. Array BioPharma Inc. Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolios and Specifications
Table 87. Array BioPharma Inc. Gastrointestinal Stromal Tumor (GIST) Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 88. Array BioPharma Inc. Main Business
Table 89. Array BioPharma Inc. Latest Developments
Table 90. Astex Pharmaceuticals, Inc. Basic Information, Gastrointestinal Stromal Tumor (GIST) Drug Manufacturing Base, Sales Area and Its Competitors
Table 91. Astex Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolios and Specifications
Table 92. Astex Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 93. Astex Pharmaceuticals, Inc. Main Business
Table 94. Astex Pharmaceuticals, Inc. Latest Developments
Table 95. Blueprint Medicines Corporation Basic Information, Gastrointestinal Stromal Tumor (GIST) Drug Manufacturing Base, Sales Area and Its Competitors
Table 96. Blueprint Medicines Corporation Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolios and Specifications
Table 97. Blueprint Medicines Corporation Gastrointestinal Stromal Tumor (GIST) Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 98. Blueprint Medicines Corporation Main Business
Table 99. Blueprint Medicines Corporation Latest Developments
Table 100. Boston Biomedical, Inc. Basic Information, Gastrointestinal Stromal Tumor (GIST) Drug Manufacturing Base, Sales Area and Its Competitors
Table 101. Boston Biomedical, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolios and Specifications
Table 102. Boston Biomedical, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 103. Boston Biomedical, Inc. Main Business
Table 104. Boston Biomedical, Inc. Latest Developments
Table 105. Calithera Biosciences, Inc. Basic Information, Gastrointestinal Stromal Tumor (GIST) Drug Manufacturing Base, Sales Area and Its Competitors
Table 106. Calithera Biosciences, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolios and Specifications
Table 107. Calithera Biosciences, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 108. Calithera Biosciences, Inc. Main Business
Table 109. Calithera Biosciences, Inc. Latest Developments
Table 110. Chipscreen Biosciences Ltd Basic Information, Gastrointestinal Stromal Tumor (GIST) Drug Manufacturing Base, Sales Area and Its Competitors
Table 111. Chipscreen Biosciences Ltd Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolios and Specifications
Table 112. Chipscreen Biosciences Ltd Gastrointestinal Stromal Tumor (GIST) Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 113. Chipscreen Biosciences Ltd Main Business
Table 114. Chipscreen Biosciences Ltd Latest Developments
Table 115. Deciphera Pharmaceuticals, LLC Basic Information, Gastrointestinal Stromal Tumor (GIST) Drug Manufacturing Base, Sales Area and Its Competitors
Table 116. Deciphera Pharmaceuticals, LLC Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolios and Specifications
Table 117. Deciphera Pharmaceuticals, LLC Gastrointestinal Stromal Tumor (GIST) Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 118. Deciphera Pharmaceuticals, LLC Main Business
Table 119. Deciphera Pharmaceuticals, LLC Latest Developments
Table 120. F. Hoffmann-La Roche Ltd. Basic Information, Gastrointestinal Stromal Tumor (GIST) Drug Manufacturing Base, Sales Area and Its Competitors
Table 121. F. Hoffmann-La Roche Ltd. Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolios and Specifications
Table 122. F. Hoffmann-La Roche Ltd. Gastrointestinal Stromal Tumor (GIST) Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 123. F. Hoffmann-La Roche Ltd. Main Business
Table 124. F. Hoffmann-La Roche Ltd. Latest Developments
Table 125. Horizon Pharma Plc Basic Information, Gastrointestinal Stromal Tumor (GIST) Drug Manufacturing Base, Sales Area and Its Competitors
Table 126. Horizon Pharma Plc Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolios and Specifications
Table 127. Horizon Pharma Plc Gastrointestinal Stromal Tumor (GIST) Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 128. Horizon Pharma Plc Main Business
Table 129. Horizon Pharma Plc Latest Developments
Table 130. Immunicum AB Basic Information, Gastrointestinal Stromal Tumor (GIST) Drug Manufacturing Base, Sales Area and Its Competitors
Table 131. Immunicum AB Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolios and Specifications
Table 132. Immunicum AB Gastrointestinal Stromal Tumor (GIST) Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 133. Immunicum AB Main Business
Table 134. Immunicum AB Latest Developments
Table 135. Jiangsu Hengrui Medicine Co., Ltd. Basic Information, Gastrointestinal Stromal Tumor (GIST) Drug Manufacturing Base, Sales Area and Its Competitors
Table 136. Jiangsu Hengrui Medicine Co., Ltd. Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolios and Specifications
Table 137. Jiangsu Hengrui Medicine Co., Ltd. Gastrointestinal Stromal Tumor (GIST) Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 138. Jiangsu Hengrui Medicine Co., Ltd. Main Business
Table 139. Jiangsu Hengrui Medicine Co., Ltd. Latest Developments
Table 140. Kolltan Pharmaceuticals, Inc. Basic Information, Gastrointestinal Stromal Tumor (GIST) Drug Manufacturing Base, Sales Area and Its Competitors
Table 141. Kolltan Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolios and Specifications
Table 142. Kolltan Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 143. Kolltan Pharmaceuticals, Inc. Main Business
Table 144. Kolltan Pharmaceuticals, Inc. Latest Developments
Table 145. Natco Pharma Limited Basic Information, Gastrointestinal Stromal Tumor (GIST) Drug Manufacturing Base, Sales Area and Its Competitors
Table 146. Natco Pharma Limited Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolios and Specifications
Table 147. Natco Pharma Limited Gastrointestinal Stromal Tumor (GIST) Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 148. Natco Pharma Limited Main Business
Table 149. Natco Pharma Limited Latest Developments
Table 150. Nerviano Medical Sciences S.r.l. Basic Information, Gastrointestinal Stromal Tumor (GIST) Drug Manufacturing Base, Sales Area and Its Competitors
Table 151. Nerviano Medical Sciences S.r.l. Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolios and Specifications
Table 152. Nerviano Medical Sciences S.r.l. Gastrointestinal Stromal Tumor (GIST) Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 153. Nerviano Medical Sciences S.r.l. Main Business
Table 154. Nerviano Medical Sciences S.r.l. Latest Developments
Table 155. Novartis AG Basic Information, Gastrointestinal Stromal Tumor (GIST) Drug Manufacturing Base, Sales Area and Its Competitors
Table 156. Novartis AG Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolios and Specifications
Table 157. Novartis AG Gastrointestinal Stromal Tumor (GIST) Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 158. Novartis AG Main Business
Table 159. Novartis AG Latest Developments
Table 160. Omeros Corporation Basic Information, Gastrointestinal Stromal Tumor (GIST) Drug Manufacturing Base, Sales Area and Its Competitors
Table 161. Omeros Corporation Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolios and Specifications
Table 162. Omeros Corporation Gastrointestinal Stromal Tumor (GIST) Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 163. Omeros Corporation Main Business
Table 164. Omeros Corporation Latest Developments
LIST OF FIGURES
Figure 1. Picture of Gastrointestinal Stromal Tumor (GIST) Drug
Figure 2. Gastrointestinal Stromal Tumor (GIST) Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Growth Rate 2020-2031 (K Pcs)
Figure 7. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Gastrointestinal Stromal Tumor (GIST) Drug Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Country/Region (2024)
Figure 10. Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Amcasertib
Figure 12. Product Picture of Anagrelide hydrochloride CR
Figure 13. Product Picture of APG-1351
Figure 14. Product Picture of Binimetinib
Figure 15. Product Picture of Others
Figure 16. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Type in 2025
Figure 17. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Type (2020-2025)
Figure 18. Gastrointestinal Stromal Tumor (GIST) Drug Consumed in Clinic
Figure 19. Global Gastrointestinal Stromal Tumor (GIST) Drug Market: Clinic (2020-2025) & (K Pcs)
Figure 20. Gastrointestinal Stromal Tumor (GIST) Drug Consumed in Hospital
Figure 21. Global Gastrointestinal Stromal Tumor (GIST) Drug Market: Hospital (2020-2025) & (K Pcs)
Figure 22. Gastrointestinal Stromal Tumor (GIST) Drug Consumed in Others
Figure 23. Global Gastrointestinal Stromal Tumor (GIST) Drug Market: Others (2020-2025) & (K Pcs)
Figure 24. Global Gastrointestinal Stromal Tumor (GIST) Drug Sale Market Share by Application (2024)
Figure 25. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Application in 2025
Figure 26. Gastrointestinal Stromal Tumor (GIST) Drug Sales by Company in 2025 (K Pcs)
Figure 27. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Company in 2025
Figure 28. Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Company in 2025 ($ millions)
Figure 29. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Company in 2025
Figure 30. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Geographic Region (2020-2025)
Figure 31. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Geographic Region in 2025
Figure 32. Americas Gastrointestinal Stromal Tumor (GIST) Drug Sales 2020-2025 (K Pcs)
Figure 33. Americas Gastrointestinal Stromal Tumor (GIST) Drug Revenue 2020-2025 ($ millions)
Figure 34. APAC Gastrointestinal Stromal Tumor (GIST) Drug Sales 2020-2025 (K Pcs)
Figure 35. APAC Gastrointestinal Stromal Tumor (GIST) Drug Revenue 2020-2025 ($ millions)
Figure 36. Europe Gastrointestinal Stromal Tumor (GIST) Drug Sales 2020-2025 (K Pcs)
Figure 37. Europe Gastrointestinal Stromal Tumor (GIST) Drug Revenue 2020-2025 ($ millions)
Figure 38. Middle East & Africa Gastrointestinal Stromal Tumor (GIST) Drug Sales 2020-2025 (K Pcs)
Figure 39. Middle East & Africa Gastrointestinal Stromal Tumor (GIST) Drug Revenue 2020-2025 ($ millions)
Figure 40. Americas Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Country in 2025
Figure 41. Americas Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Country (2020-2025)
Figure 42. Americas Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Type (2020-2025)
Figure 43. Americas Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Application (2020-2025)
Figure 44. United States Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth 2020-2025 ($ millions)
Figure 45. Canada Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth 2020-2025 ($ millions)
Figure 46. Mexico Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth 2020-2025 ($ millions)
Figure 47. Brazil Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth 2020-2025 ($ millions)
Figure 48. APAC Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Region in 2025
Figure 49. APAC Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Region (2020-2025)
Figure 50. APAC Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Type (2020-2025)
Figure 51. APAC Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Application (2020-2025)
Figure 52. China Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth 2020-2025 ($ millions)
Figure 53. Japan Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth 2020-2025 ($ millions)
Figure 54. South Korea Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth 2020-2025 ($ millions)
Figure 55. Southeast Asia Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth 2020-2025 ($ millions)
Figure 56. India Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth 2020-2025 ($ millions)
Figure 57. Australia Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth 2020-2025 ($ millions)
Figure 58. China Taiwan Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth 2020-2025 ($ millions)
Figure 59. Europe Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Country in 2025
Figure 60. Europe Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Country (2020-2025)
Figure 61. Europe Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Type (2020-2025)
Figure 62. Europe Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Application (2020-2025)
Figure 63. Germany Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth 2020-2025 ($ millions)
Figure 64. France Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth 2020-2025 ($ millions)
Figure 65. UK Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth 2020-2025 ($ millions)
Figure 66. Italy Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth 2020-2025 ($ millions)
Figure 67. Russia Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth 2020-2025 ($ millions)
Figure 68. Middle East & Africa Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Country (2020-2025)
Figure 69. Middle East & Africa Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Type (2020-2025)
Figure 70. Middle East & Africa Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Application (2020-2025)
Figure 71. Egypt Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth 2020-2025 ($ millions)
Figure 72. South Africa Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth 2020-2025 ($ millions)
Figure 73. Israel Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth 2020-2025 ($ millions)
Figure 74. Turkey Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth 2020-2025 ($ millions)
Figure 75. GCC Countries Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth 2020-2025 ($ millions)
Figure 76. Manufacturing Cost Structure Analysis of Gastrointestinal Stromal Tumor (GIST) Drug in 2025
Figure 77. Manufacturing Process Analysis of Gastrointestinal Stromal Tumor (GIST) Drug
Figure 78. Industry Chain Structure of Gastrointestinal Stromal Tumor (GIST) Drug
Figure 79. Channels of Distribution
Figure 80. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Forecast by Region (2026-2031)
Figure 81. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share Forecast by Region (2026-2031)
Figure 82. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share Forecast by Type (2026-2031)
Figure 83. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share Forecast by Type (2026-2031)
Figure 84. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share Forecast by Application (2026-2031)
Figure 85. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share Forecast by Application (2026-2031)
Figure 1. Picture of Gastrointestinal Stromal Tumor (GIST) Drug
Figure 2. Gastrointestinal Stromal Tumor (GIST) Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Growth Rate 2020-2031 (K Pcs)
Figure 7. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Gastrointestinal Stromal Tumor (GIST) Drug Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Country/Region (2024)
Figure 10. Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Amcasertib
Figure 12. Product Picture of Anagrelide hydrochloride CR
Figure 13. Product Picture of APG-1351
Figure 14. Product Picture of Binimetinib
Figure 15. Product Picture of Others
Figure 16. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Type in 2025
Figure 17. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Type (2020-2025)
Figure 18. Gastrointestinal Stromal Tumor (GIST) Drug Consumed in Clinic
Figure 19. Global Gastrointestinal Stromal Tumor (GIST) Drug Market: Clinic (2020-2025) & (K Pcs)
Figure 20. Gastrointestinal Stromal Tumor (GIST) Drug Consumed in Hospital
Figure 21. Global Gastrointestinal Stromal Tumor (GIST) Drug Market: Hospital (2020-2025) & (K Pcs)
Figure 22. Gastrointestinal Stromal Tumor (GIST) Drug Consumed in Others
Figure 23. Global Gastrointestinal Stromal Tumor (GIST) Drug Market: Others (2020-2025) & (K Pcs)
Figure 24. Global Gastrointestinal Stromal Tumor (GIST) Drug Sale Market Share by Application (2024)
Figure 25. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Application in 2025
Figure 26. Gastrointestinal Stromal Tumor (GIST) Drug Sales by Company in 2025 (K Pcs)
Figure 27. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Company in 2025
Figure 28. Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Company in 2025 ($ millions)
Figure 29. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Company in 2025
Figure 30. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Geographic Region (2020-2025)
Figure 31. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Geographic Region in 2025
Figure 32. Americas Gastrointestinal Stromal Tumor (GIST) Drug Sales 2020-2025 (K Pcs)
Figure 33. Americas Gastrointestinal Stromal Tumor (GIST) Drug Revenue 2020-2025 ($ millions)
Figure 34. APAC Gastrointestinal Stromal Tumor (GIST) Drug Sales 2020-2025 (K Pcs)
Figure 35. APAC Gastrointestinal Stromal Tumor (GIST) Drug Revenue 2020-2025 ($ millions)
Figure 36. Europe Gastrointestinal Stromal Tumor (GIST) Drug Sales 2020-2025 (K Pcs)
Figure 37. Europe Gastrointestinal Stromal Tumor (GIST) Drug Revenue 2020-2025 ($ millions)
Figure 38. Middle East & Africa Gastrointestinal Stromal Tumor (GIST) Drug Sales 2020-2025 (K Pcs)
Figure 39. Middle East & Africa Gastrointestinal Stromal Tumor (GIST) Drug Revenue 2020-2025 ($ millions)
Figure 40. Americas Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Country in 2025
Figure 41. Americas Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Country (2020-2025)
Figure 42. Americas Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Type (2020-2025)
Figure 43. Americas Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Application (2020-2025)
Figure 44. United States Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth 2020-2025 ($ millions)
Figure 45. Canada Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth 2020-2025 ($ millions)
Figure 46. Mexico Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth 2020-2025 ($ millions)
Figure 47. Brazil Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth 2020-2025 ($ millions)
Figure 48. APAC Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Region in 2025
Figure 49. APAC Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Region (2020-2025)
Figure 50. APAC Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Type (2020-2025)
Figure 51. APAC Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Application (2020-2025)
Figure 52. China Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth 2020-2025 ($ millions)
Figure 53. Japan Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth 2020-2025 ($ millions)
Figure 54. South Korea Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth 2020-2025 ($ millions)
Figure 55. Southeast Asia Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth 2020-2025 ($ millions)
Figure 56. India Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth 2020-2025 ($ millions)
Figure 57. Australia Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth 2020-2025 ($ millions)
Figure 58. China Taiwan Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth 2020-2025 ($ millions)
Figure 59. Europe Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Country in 2025
Figure 60. Europe Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Country (2020-2025)
Figure 61. Europe Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Type (2020-2025)
Figure 62. Europe Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Application (2020-2025)
Figure 63. Germany Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth 2020-2025 ($ millions)
Figure 64. France Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth 2020-2025 ($ millions)
Figure 65. UK Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth 2020-2025 ($ millions)
Figure 66. Italy Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth 2020-2025 ($ millions)
Figure 67. Russia Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth 2020-2025 ($ millions)
Figure 68. Middle East & Africa Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Country (2020-2025)
Figure 69. Middle East & Africa Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Type (2020-2025)
Figure 70. Middle East & Africa Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Application (2020-2025)
Figure 71. Egypt Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth 2020-2025 ($ millions)
Figure 72. South Africa Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth 2020-2025 ($ millions)
Figure 73. Israel Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth 2020-2025 ($ millions)
Figure 74. Turkey Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth 2020-2025 ($ millions)
Figure 75. GCC Countries Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth 2020-2025 ($ millions)
Figure 76. Manufacturing Cost Structure Analysis of Gastrointestinal Stromal Tumor (GIST) Drug in 2025
Figure 77. Manufacturing Process Analysis of Gastrointestinal Stromal Tumor (GIST) Drug
Figure 78. Industry Chain Structure of Gastrointestinal Stromal Tumor (GIST) Drug
Figure 79. Channels of Distribution
Figure 80. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Forecast by Region (2026-2031)
Figure 81. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share Forecast by Region (2026-2031)
Figure 82. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share Forecast by Type (2026-2031)
Figure 83. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share Forecast by Type (2026-2031)
Figure 84. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share Forecast by Application (2026-2031)
Figure 85. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share Forecast by Application (2026-2031)
